| answer text |
<p>We are aware of a supply issue with Ozempic. We have issued guidance in the form
of Medicine Supply Notifications and, on 18 July 2023, issued a National Patient Safety
Alert with advice for healthcare professionals on how to manage patients requiring
this medicine. Our guidance is clear that glucagon-like peptide 1 receptor agonist
medicines, such as Ozempic, that are solely licensed to treat Type 2 diabetes should
only be used for that purpose and should not be routinely prescribed for weight loss.</p><p>The
General Pharmaceutical Council, General Medical Council, Health and Care Professions
Council, Nursing and Midwifery Council and Pharmaceutical Society of Northern Ireland
have also issued a joint statement stressing the importance of health and care professionals
meeting regulatory standards in relation to these medicines. We have also added some
of these products to the list of medicines that cannot be exported from, or hoarded
in, the United Kingdom.</p><p>We are continuing to work closely with manufacturers
and others working in the supply chain to help ensure the continued supply of these
medicines for patients in the UK, for example by asking suppliers to expedite deliveries.
We have provided advice for healthcare professionals on how to manage patients requiring
this medicine whilst there are shortages and are keeping this under review as the
situation evolves. If any patient is concerned about their treatment, they should
discuss this with their clinician at the earliest opportunity.</p>
|
|
